Scientific Advisory Board

We aim to stay in the frontline of the fast-moving field of oligonucleotide therapeutics. Our Scientific Advisory Board (SAB) is a group of world-leading experts in drug discovery and clinical development with particular expertise in the rare disease space. The SAB challenges us to excel at siRNA molecular design, drug discovery, and development

Carousel_2.jpg

Professor Sir Gordon Duff, MD PhD

Chairman of the SAB

Carousel_3.jpg

Professor Annemieke Aartsma-Rus, PhD

Member of the SAB

AboutUs1.jpg

Professor Henry Ginsberg, MD PhD

Member of the SAB

Image 6b.png

Professor John Porter, MD PhD

Member of the SAB

Professor Sir Gordon Duff, MD PhD

Chairman of the SAB

Sir Gordon is the Principal of St Hilda’s college at the University Oxford and previously served as Chair of the UK's Committee on Safety of Medicines and its Biologicals and Vaccines Sub-committee as well as inaugural Chair of the UK's Commission on Human Medicines. Sir Gordon is an expert on healthcare and UK science policy with a special interest in the genetics of the inflammatory response and was co-founding editor of the international research journal CYTOKINE, advisory editor to the Human Genome Organisation (HUGO) journal, and is Past-President of the International Cytokine Society. He was Knighted for services to Public Health in 2007, has more than 450 peer-reviewed publications, and was listed in the ‘Top 100’ working scientists in the UK Science Council’s list for 2014. He was also previously Chair of the Biotechnology and Biological Science Research Council (BBSRC) and of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), and so brings deep insights and a regulatory perspective of biopharma, drug discovery and drug development.

Carousel_2.jpg

Professor Annemieke Aartsma-Rus, PhD

Member of the SAB

Annemieke is Professor of Translational Genetics at Leiden University as well as President of the Oligonucleotide Therapeutics Society (OTS) and chair of TREAT-NMD; a network for the neuromuscular field that provides an infrastructure to ensure that the most promising new therapies reach patients as quickly as possible. Annemieke is a world leading expert in exon skipping therapies and played an important role in the development of the antisense mediated exon skipping therapy for Duchenne muscular dystrophy already during her PhD research, and remains a scientific advisor for several Duchenne organizations. Her work to date has resulted in a deep knowledge about potential pitfalls in oligonucleotide therapeutic drug discovery and development, and as President of OTS Annemieke is well respected in the whole oligonucleotide therapeutics field.

Carousel_3.jpg

Professor Henry Ginsberg, MD PhD

Member of the SAB

Henry is Professor of Medicine at Columbia University and has been so for the last 35 years, and a past Director for the Irving Institute for Clinical & Translational Research. Henry is an active senior investigator of cardiovascular disease and lipoprotein metabolism research with detailed knowledge about Lp(a) (the target for our pipeline project SLN360) but also all the drug development in the cardiovascular disease and lipoprotein metabolism field that has preceded it – the successes and the failures in a complicated area of disease. Henry has over 300 peer reviewed and invited publications and serves as the Chief Medical Officer for the Lp(a) Foundation, a key partner in development of drugs targeting Lp(a).

AboutUs1.jpg

Professor John Porter, MD PhD

Member of the SAB

John is professor of Haematology and Consultant Haematologist at the University College London Hospitals in London, UK and head of the joint Red Cell Unit for UCLH and Whittington Hospitals. He has served as scientific adviser to the British Society of Haematology, the UK Thalassaemia Society, the Thalassaemia International Federation (TIF), and to grant review and advisory panels at the NIH in Bethesda, MD, USA. He has published more than 350 peer-reviewed articles and made numerous contributions to books, as well as clinical guidelines and other medical articles. John’s clinical and research focus has been treatments of thalassaemia and sickle cell disorders, with particular reference to iron overload, the mechanisms of iron chelation, the speciation and uptake of non-transferrin-bound iron (NTBI) species, the molecular basis of iron homeostasis in health and disease, and the actions and toxicities of mixed-ligand chelation therapies. As a world leading haematology KOL John brings essential practical knowledge relevant for our pipeline program SLN124.

Image 6b.png